How to Word FDA Status on a PRP Consent Form
How should a consent form explain that PRP for hair loss is not an FDA-cleared indication?
Most practices get into trouble here not because they lied, but because they were vague. Your patient is about to pay out of pocket for something no agency has ever looked at for this purpose, and the paragraph you hand them has to say that plainly without sounding like a warning you don't mean. Keep it short, keep it in the words a patient would actually use, and make it do three jobs in order.
- Separate the equipment from the treatment: The centrifuge, tubes and separation kits hold FDA clearance as blood-handling devices, and the cleared purpose written into most of those submissions describes preparing platelet-rich plasma to mix with bone graft material in orthopedic and dental surgery, not injection into the scalp.
- State the treatment's status in one unhedged sentence: The FDA hasn't approved or cleared platelet-rich plasma injections as a treatment for androgenetic alopecia or any other form of hair loss, and no agency review has evaluated the procedure for that purpose.
- Explain what that does and doesn't mean: A licensed clinician may lawfully provide a treatment the agency hasn't evaluated as part of the practice of medicine, the absence of clearance isn't a finding that the treatment is unsafe or ineffective, and it's equally not evidence that the treatment works.
A defensible disclosure separates the cleared blood-handling device from the treatment itself, states in one unhedged sentence that the FDA has not approved or cleared platelet-rich plasma injections for any form of hair loss, and then explains that the absence of clearance is neither a safety finding nor evidence the treatment works.
What does FDA clearance actually cover when a device is used to prepare platelet-rich plasma?
There's a gap between what the clearance letter in your file cabinet actually says and what people assume it says, and that gap is where bad consent language comes from. The agency looked at whether the centrifuge separates blood safely and predictably. It never looked at whether the preparation that comes out of it grows hair.
- The 510(k) pathway: Shows a device is substantially equivalent to one already sold, not that any clinical outcome follows.
- The cleared labeling: Preparing platelet-rich plasma to mix with bone graft material at the point of care.
- What clearance attaches to: The equipment itself, never the plasma you inject into the scalp.
- The minimal manipulation line: Activators, scaffolds or culture steps push the preparation toward drug or biologic regulation.
Clearance for a platelet concentration system covers the device's ability to separate blood under a substantial equivalence review, with labeling written around mixing the preparation with bone graft material in orthopedic and oral surgery, and it never attaches to the plasma that comes out of the machine.
What is the difference between off-label use of a cleared device and an unapproved treatment?
Off-label is a precise term that gets stretched well past where it fits, and stretching it is expensive. Off-label means a product the agency authorized for something is being used for something else, which is lawful and routine. A platelet injection for hair loss sits next door to that, not inside it, because the treatment itself was never authorized for anything.
| Question | Off-label use of a cleared device | Unapproved treatment |
|---|---|---|
| Authorization | Product is authorized, used outside that labeling | Never authorized for any indication |
| Accurate wording | "Cleared for a different purpose" | "Not evaluated or authorized for hair loss" |
| Standard of care | Unchanged, prudent practitioner test applies | Unchanged, and novelty often raises the disclosure burden |
| Insurance | Sometimes covered | Almost never covered |
Using a cleared centrifuge on the scalp is genuinely an off-label use of that equipment, but the injection itself has never been authorized for any indication, so a form that says "FDA approved for off-label use" is internally contradictory and borrows an authority that does not exist.
What plain-language wording states regulatory status without frightening or misleading the patient?
A regulatory paragraph that runs half a page gets skimmed, and a skimmed disclosure is worth very little when someone asks a year later what your patient understood. Aim for a sixth to eighth grade reading level and about four short declarative sentences. Here's the order that holds up.
- Name what's cleared: "The equipment used to prepare your platelets is cleared by the FDA for separating blood."
- State the treatment's status: "The FDA has not approved this injection as a treatment for hair loss."
- Say what that means: "That means the agency has not reviewed it for this use."
- Say both halves of the consequence: "This does not mean the treatment is illegal or unsafe, and it does not mean the treatment has been shown to work."
Keep the regulatory paragraph to roughly four short declarative sentences at a sixth to eighth grade reading level, strike hedges like "technically" and "simply," and always say both halves, since leaving out the first reads as a warning you don't intend and leaving out the second reads as reassurance the evidence can't support.
Which phrasings misstate the regulatory position and create legal exposure?
Every phrase below started life as someone trying to sound confident, and every one of them reads differently out loud in a deposition than it did on the website. The test a regulator or a jury applies isn't whether each word was accurate. It's the impression a reasonable person walked away with.
"FDA approved" is the single most damaging phrase a hair loss consent form can carry, because approval and clearance are different regulatory acts and a disclaimer in six point type under a bold promise does not cure the promise.
Where in a consent document should the regulatory disclosure sit so it is not buried?
Placement is what decides whether a disclosure gets read, and reading is the only thing that makes it a disclosure instead of a paragraph. Put it where your patient has enough context to understand it and hasn't yet hit the dense clinical material where attention falls off a cliff.
- Position in the form: Immediately after the plain description of the procedure and before the risk list.
- Its own heading and initial line: An initial beside a specific paragraph is evidence about that paragraph.
- A second appearance: Repeat it in the alternatives section, where approved options sit beside this one.
- Electronic platforms: Its own screen, a required acknowledgment, and a timestamped record of what was viewed.
Place the regulatory statement immediately after the plain description of the procedure and before the risk list, give it its own heading and its own initial line, and repeat it once in the alternatives section, because a single signature at the end of a six page document is evidence only that your patient signed a six page document.
How do state informed consent standards treat disclosure of a treatment's regulatory status?
Which state you're practicing in changes how much you have to say, and the difference isn't small. States split roughly into two camps, and one of them measures your disclosure from your patient's side of the table rather than from professional custom. Regulatory status happens to land squarely inside the more demanding of the two.
| Question | Reasonable physician standard | Reasonable patient standard |
|---|---|---|
| The test | What a prudent practitioner in the specialty customarily discloses | What a reasonable person in this patient's position would find material |
| Anchored to | Professional custom | The patient's decision |
| Regulatory status | Custom decides whether it comes up | Elective, uncovered and unevaluated is plainly material |
| Practical demand on the form | Lower | Considerably higher |
Under the reasonable patient standard used in many states, the test is what a person in this patient's position would consider material, and an elective, self-funded procedure that no agency has evaluated and no insurer covers for that same reason sits squarely inside it.
What should the form say about the strength of the evidence behind the procedure?
The literature here is real but modest, and your form should describe it that way rather than reaching for a number. Reviews keep reporting improvement in density across most studies examined while flagging high heterogeneity, which is a polite way of saying the studies aren't measuring the same intervention.
- Study size: Small randomized or split-scalp designs, commonly a few dozen participants each.
- Follow-up window: Usually three to six months, with outcome measures differing from paper to paper.
- Why results scatter: Concentration, activation, spin protocol, injection depth and session interval aren't standardized.
- Durability: Benefit fades without repeat sessions, and stopping returns your patient toward the underlying trajectory.
Describe the evidence by its shape rather than by a percentage, since many patients in published studies saw some increase in density, some saw no change, follow-up rarely runs past six months, and no study design lets you predict which group an individual patient will fall into.
How should the form record that the patient understood and had the chance to ask questions?
"I have read and understood the above" proves less than most practices assume. It establishes that your patient signed under a sentence, and the standard response is that they signed what was handed to them without reading it. The strongest records add something your patient couldn't have produced by reflex.
Record the specific questions the patient asked along with a teach-back line restating the regulatory statement in the patient's own words, and retain the signed version of the form under the state's medical record rules, because a restatement the patient produced themselves carries weight no attestation line can.
How does the regulatory disclosure interact with advertising and marketing claims made elsewhere?
Three different authorities can read the same sentence you wrote. State boards govern professional advertising under licensing rules, the FTC wants competent and reliable scientific evidence behind a health claim before it's published, and the FDA's interest attaches where a promotional statement amounts to a claim about a regulated product's intended use. The common thread is substantiation, so run one claim across every surface it appears on and fix what doesn't match.
State boards, the FTC and the FDA can each review the same advertising claim, and all of them judge the net impression a reasonable consumer takes away, which is why fine print under a bold promise does not cure the promise and why a single named owner of the approved language, usually the medical director, is the practical control.
